INSOMNIA,
Western Medicine

Health Interests

Western medicine view of insomnia

Clinical insomnia is defined by repeated difficulty falling asleep, staying asleep, or waking too early, paired with daytime impairment, and it is diagnosed mainly by clinical history, sleep diary, and screening for comorbid sleep, psychiatric, medical, and substance-related causes.

Gold standard
CBT-I
Routine PSG?
No
Drug role
Adjunct / selective
Best durability
Behavioral
Definition & assessment

How Western medicine defines and diagnoses insomnia

Diagnosis is based on history, sleep patterns, and ruling out mimics.

Core definition
Night difficulty + daytime impairment
Problems initiating sleep, maintaining sleep, or early awakening count when they impair daytime function.
Main diagnostic tool
Clinical interview
Sleep history, medical and psychiatric review, substance review, and symptom context are central.
Helpful add-ons
2-week diary
Questionnaires and sleep logs help quantify severity and patterns.
Polysomnography
Not routine
Used mainly when another sleep disorder is suspected or treatment fails.

Diagnostic workflow

  • Document sleep-onset delay, awakenings, early waking, frequency, duration, and daytime effects.
  • Review comorbid depression, anxiety, pain, sleep apnea, restless legs, medications, alcohol, and stimulants.
  • Use sleep diary and validated questionnaires to track severity and response.
  • Reserve PSG for uncertainty, suspected apnea or movement disorder, paradoxical insomnia, or treatment failure.
Treatment standards

Top insomnia treatments, expected effects, duration, and risks

First-line Medication option Use caution

CBT-I

Gold standard

Effect: strong short-term symptom improvement and better long-term durability than hypnotics; often around a 50% reduction in insomnia symptoms in meta-analytic estimates.

Duration: usually delivered over 4-8 weeks, then skills are continued by the patient rather than taken forever.

Side effects / downsides: no drug adverse effects, but sleep restriction can cause temporary daytime sleepiness, irritability, and adherence difficulty early on.

PubMed / PMC: 38016484, PMC10002474, PMC6796223

Hypnotic medications

Selective use

Effect: can improve sleep initiation or maintenance in the short term, but durability after stopping is usually worse than CBT-I.

Duration: generally intended for short-term or carefully selected ongoing use with reassessment, not automatic lifelong administration.

Side effects / downsides: sedation, cognitive impairment, falls, parasomnias, residual next-day effects, tolerance, and dependence risk vary by agent.

PubMed: 27998379; guideline context from 38016484

Combination treatment

Case dependent

Effect: CBT-I started first tends to outperform medication-first strategies for long-term remission; combination can help some patients but is not clearly superior to CBT-I alone.

Duration: drugs may be tapered while behavioral strategies continue.

Side effects / downsides: medication-related adverse effects still apply if drugs are used.

PMC11804918; PMC13076838

Western medicine takeaways

  • Gold standard for chronic insomnia is CBT-I, not routine long-term sedative use.
  • Medications can help symptoms quickly, but they often act more like symptom suppressors than durable fixes.
  • Ongoing reassessment matters because insomnia is often linked with comorbid sleep apnea, psychiatric illness, pain, or substance use.
  • PSG is not the standard diagnostic starting point for uncomplicated chronic insomnia.

Watch The Full Explanation